ClinicalTrials.gg
CompletedNCT04811716Updated Apr 8, 2025Results posted

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

A Phase 2 interventional study of Pozelimab and Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2021
with 1 other
Phase 2
3 of 10
none open now
Registered
3rd of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2021, is one of 3 in phase 2, and was the 3rd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and tolerability of 2 dosing regimens of pozelimab and cemdisiran combination therapy during the open-label treatment period (OLTP)

The secondary objectives of the study are:

  • To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control, breakthrough hemolysis, and inhibition of total complement hemolysis activity (CH50)
  • To evaluate the effect of the combination treatment on hemoglobin levels
  • To evaluate the effect of the combination treatment on red blood cell (RBC) transfusion requirements
  • To evaluate the effect of the combination treatment on clinical outcome assessments (COAs) measuring fatigue and health related quality of life
  • To assess the concentrations of total pozelimab in serum and total complement component (C) 5 and cemdisiran in plasma
  • To assess immunogenicity to pozelimab and cemdisiran
  • To evaluate the long-term safety and efficacy of pozelimab and cemdisiran in an optional open-label extension period (OLEP)
  • To assess safety after treatment intensification with pozelimab and cemdisiran
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants with PNH who are receiving treatment with pozelimab monotherapy in the R3918- PNH-1868 study (NCT04162470)

Key Exclusion Criteria:

  1. Documented, positive polymerase chain reaction (PCR) or equivalent test based on regional recommendations for COVID-19 or suspected SARS-CoV-2 infection as defined in the protocol
  2. Participants with documented history of liver cirrhosis or participants with liver disease with evidence of currently impaired liver function; or participants with (ALT) or aspartate aminotransferase (AST) as described in the protocol
  3. Significant protocol deviation(s) in the parent study based on the investigator's judgment as described in the protocol
  4. Any new condition or worsening of an existing condition which, in the opinion of the investigator, would make the participant unsuitable for enrollment or would jeopardize the safety of the participant
  5. Known to cemdisiran or any component of cemdisiran formulation

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Pozelimab Q4W + Cemdisiran

    Drug: Pozelimab · Drug: Cemdisiran

  • Experimental
    Pozelimab Q2W + Cemdisiran

    Drug: Pozelimab · Drug: Cemdisiran

Interventions

  • Administered Sub-cutaneous (SC) per protocol

    Also known as: REGN3918

  • Administered SC per protocol

    Also known as: ALN-CC5

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Open Label Treatment Period (OLTP)

    Time frame: Through Week 28

Secondary outcomes

  1. Percent Change of Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period

    OLTP Pre-treatment (mean of LDH values prior to combination dosing); End-of-treatment (mean of LDH value at week 24- through week 28); percentage of change in Upper Limit of Normal (xULN).

    Time frame: End of treatment period, approximately 28 Weeks

  2. Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1) Through Week 28

    OLTP Adequate control of hemolysis is defined as LDH values ≤1.5 × Upper limit of normal (ULN) from baseline (day 1) to week 28

    Time frame: Baseline (Day 1) through Week 28

  3. Percentage of Participants Maintaining Adequate Control of Hemolysis From Week 4 Through Week 28

    OLTP

    Time frame: Week 4 through Week 28

  4. Percentage of Participants With Adequate Control of Hemolysis at Each Visit Day 1 Through Week 28

    OLTP; Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit

    Time frame: Day 1 through Week 28

  5. Percentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1) Through Week 28

    OLTP; Normalization of LDH was defined as LDH ≤1.0 × ULN at each visit

    Time frame: Baseline (Day 1) through Week 28

  6. Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Baseline (Day 1) Through Week 28

    OLTP

    Time frame: Baseline (Day 1) through Week 28

  7. Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Week 4 Through Week 28

    OLTP

    Time frame: Week 4 through Week 28

  8. Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1) Through Week 28

    OLTP Breakthrough hemolysis is defined as an increase in LDH with concomitant signs or symptoms associated with hemolysis: • An increase in LDH occurs when: * LDH ≥2 × ULN if pre-treatment LDH is ≤1.5 × ULN or * LDH ≥2 × ULN after initial achievement of LDH ≤1.5 × ULN if pre-treatment LDH is \>1.5 × ULN Signs or symptoms should correspond to those known to be associated with intravascular hemolysis due to Paroxysmal nocturnal hemoglobinuria (PNH) limited to the following: new onset or worsening fatigue, headache, dyspnea, hemoglobinuria, abdominal pain, scleral icterus, erectile dysfunction, chest pain, confusion, dysphagia, anemia including hemoglobin value significantly lower (ie, ≥2g/dL decrease) compared to patient's known baseline hemoglobin values, and thrombotic event.

    Time frame: Baseline (Day 1) through Week 28

  9. Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1) Through Week 28

    OLTP Hemoglobin stabilization was defined as participants who did not receive an RBC transfusion and had no decrease in hemoglobin level of ≥2 grams per deciLiter (g/dL).

    Time frame: Baseline (Day 1) through Week 28

  10. Change in Hemoglobin Levels From Baseline (Day 1) Through Week 28

    OLTP

    Time frame: Baseline (Day 1) to Week 28

  11. Percentage of Participants With Transfusion Avoidance From Baseline (Day 1) Through Week 28

    OLTP Not requiring a red blood cell (RBC) transfusion as per protocol algorithm

    Time frame: Baseline (Day 1) to Week 28

  12. Rate of Red Blood Cells (RBCs) Transfused From Baseline (Day 1) to Week 28

    OLTP Rate of RBCs transfused is defined as number of events per person-years of treatment. For each participant, the participant-years are the time from first dose date to week 28 (or early terminations visit if subject discontinued the study early) in the OLTP.

    Time frame: Baseline (Day 1) to Week 28

  13. Number of Per-Protocol RBC Units Transfused From Baseline (Day 1) Through Week 28

    OLTP

    Time frame: Baseline (Day 1) to Week 28

  14. Change in Total Complement Hemolysis Activity Assay (CH50) From Baseline (Day 1) Through Week 28

    OLTP

    Time frame: Baseline (Day 1) to Week 28

  15. Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1) Through Week 28

    OLTP FACIT fatigue is a 13-item scale and for each item 4 is not at all fatigued to 0 very much fatigued. Higher FACIT-Fatigue scores indicate less fatigue (scores range from 0-52). A 5-point change is considered clinically meaningful.

    Time frame: Baseline (Day 1) to Week 28

  16. Change in Global Health Status/Quality of Life Scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire Core 30 Items (EORTC QLQ-C30) From Baseline (Day 1) Through Week 28

    OLTP EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

    Time frame: Baseline (Day 1) to Week 28

  17. Change in Physical Function (PF) Scores on the EORTC QLQ-C30 From Baseline (Day 1) Through Week 28

    OLTP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

    Time frame: Baseline (Day 1) to Week 28

  18. Concentrations of Total Pozelimab in Serum on Week 28

    OLTP

    Time frame: On Week 28

  19. Concentrations of Cemdisiran in Plasma on Week 28

    OLTP

    Time frame: On Week 28

  20. Concentrations of Total C5 on Week 28

    OLTP

    Time frame: On Week 28

  21. Number of Participants With Pozelimab Anti-Drug Antibody (ADA) Responses Over Time

    OLTP and OLEP

    Time frame: Up to Week 52 (OLTP [ Week 0 - Week 28] + OLEP [Week 28 - Week 52])

  22. Number of Participants With Cemdisiran Anti-Drug Antibody (ADA) Responses Over Time

    OLTP and OLEP

    Time frame: Up to Week 52 (OLTP [ Week 0 - Week 28] + OLEP [Week 28 - Week 52])

  23. Percentage of Participants With TEAEs for Participants Who Received Treatment Intensification

    OLTP No participants received dose intensification during the study; Therefore, assessment of the safety of pozelimab + cemdisiran combination therapy in participants requiring dose intensification was not conducted.

    Time frame: Through Week 28

  24. Change of LDH From Baseline (Day 1e) to Week 24e

    Optional Open-Label Extension Period (OLEP)

    Time frame: Baseline (Day 1e) to Week 24e

  25. Percent Change of LDH From OLEP Baseline (Day 1e) to Week 24e

    OLEP; Percentage of change for units per liter (U/L)

    Time frame: Baseline (Day 1e) to Week 24e

  26. Change of LDH From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  27. Percent Change of LDH From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  28. Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 24e

    OLEP

    Time frame: Baseline (Day 1e) through Week 24e

  29. Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 52e

    OLEP

    Time frame: Baseline (Day 1e) through Week 52e

  30. Percentage of Participants With Adequate Control of Hemolysis at Each Visit From Baseline (Day 1e) Through Week 52e

    OLEP Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit

    Time frame: Baseline (Day 1e) through Week 52e

  31. Percentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1e) Through Week 52e

    OLEP

    Time frame: Baseline (Day 1e) through week 52e

  32. Average LDH (U/L) Based on Area Under the Curve (AUC) From OLEP Baseline (Day 1e) Through Week 52e

    OLEP

    Time frame: Baseline (Day 1e) through Week 52e

  33. Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 24e

    OLEP

    Time frame: Baseline (Day 1e) through Week 24e

  34. Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 52e

    OLEP

    Time frame: Baseline (Day 1e) through Week 52e

  35. Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 24e

    OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels

    Time frame: Baseline (Day 1e) through Week 24e

  36. Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 52e

    OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels

    Time frame: Baseline (Day 1e) through Week 52e

  37. Change in Hemoglobin Levels From Baseline (Day 1e) to Week 24e

    OLEP

    Time frame: Baseline (Day 1e) to Week 24e

  38. Change in Hemoglobin Levels From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  39. Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 24e

    OLEP Not requiring a RBC transfusion as per protocol algorithm

    Time frame: Baseline (Day 1e) through Week 24e

  40. Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 52e

    OLEP Not requiring a RBC transfusion as per protocol algorithm

    Time frame: Baseline (Day 1e) to Week 52e

  41. Rate of RBCs Transfused From Baseline (Day 1e) to Week 24e

    OLEP

    Time frame: Baseline (Day 1e) to Week 24e

  42. Rate of RBCs Transfused From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  43. Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 24e

    OLEP

    Time frame: Baseline (Day 1e) to Week 24e

  44. Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  45. Change in CH50 From Baseline (Day 1e) to Week 16e

    OLEP

    Time frame: Baseline (Day 1e) to Week 16e

  46. Change in CH50 From Baseline (Day 1e) to Week 24e

    OLEP

    Time frame: Baseline (Day 1e) to Week 24e

  47. Change in CH50 From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  48. Percent Change in CH50 From Baseline (Day 1e) to Week 16e

    OLEP

    Time frame: Baseline (Day 1e) to Week 16e

  49. Percent Change in CH50 From Baseline (Day 1e) to Week 24e

    OLEP

    Time frame: Baseline (Day 1e) to Week 24e

  50. Percent Change in CH50 From Baseline (Day 1e) to Week 52e

    OLEP

    Time frame: Baseline (Day 1e) to Week 52e

  51. Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1e) to Week 52e

    OLEP; The FACIT-Fatigue is a 13-item, self-administered assessment of an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-Fatigue items are measured with a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating less fatigue. A 5-point change is considered clinically meaningful.

    Time frame: Baseline (Day 1e) to Week 52e

  52. Change in GHS/QoL on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e

    OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

    Time frame: Baseline (Day 1e) to Week 52e

  53. Change in PF Scores on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e

    OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

    Time frame: Baseline (Day 1e) to Week 52e

  54. Percentage of Participants With TEAEs Up to Week 52

    OLEP

    Time frame: Up to Week 52

  55. Concentrations of Total Pozelimab in Serum on Week 52

    OLEP

    Time frame: On Week 52

  56. Concentrations of Total C5 on Week 52

    OLEP

    Time frame: On Week 52

  57. Concentrations of Cemdisiran in Plasma on Week 52

    OLEP

    Time frame: On Week 52

07

Results

Posted Jan 16, 2025

Participant flow

Participant flow — Overall Study
MilestonePozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Started1212
Completed1012
Not completed20
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)

Open Label Treatment Period (OLTP)

Time frame:
Through Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Participants with any TEAE66.741.7
Participants with serious TEAE16.70
Participants with severe TEAE16.70
SecondaryPercent Change of Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period

OLTP Pre-treatment (mean of LDH values prior to combination dosing); End-of-treatment (mean of LDH value at week 24- through week 28); percentage of change in Upper Limit of Normal (xULN).

Time frame:
End of treatment period, approximately 28 Weeks
Reported as:
Mean · Percentage of change
Percent Change of Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period
Percentage of changePozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Percent Change of Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period2.93 ± 36.5753.65 ± 13.608
SecondaryPercentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1) Through Week 28

OLTP Adequate control of hemolysis is defined as LDH values ≤1.5 × Upper limit of normal (ULN) from baseline (day 1) to week 28

Time frame:
Baseline (Day 1) through Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1) Through Week 28
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1) Through Week 2875.091.7
SecondaryPercentage of Participants Maintaining Adequate Control of Hemolysis From Week 4 Through Week 28

OLTP

Time frame:
Week 4 through Week 28
Reported as:
Number · Percentage of Participants
Percentage of Participants Maintaining Adequate Control of Hemolysis From Week 4 Through Week 28
Percentage of ParticipantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Percentage of Participants Maintaining Adequate Control of Hemolysis From Week 4 Through Week 2883.391.7
SecondaryPercentage of Participants With Adequate Control of Hemolysis at Each Visit Day 1 Through Week 28

OLTP; Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit

Time frame:
Day 1 through Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Adequate Control of Hemolysis at Each Visit Day 1 Through Week 28
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Baseline Visit (Day 1)100.0100.0
Pre-treatment100.0100.0
Week 1100.0100.0
Week 2100.0100.0
Week 483.0100.0
Week 692.0100.0
Week 8100.0100.0
Week 10100.0100.0
Week 12100.092.0
Week 16100.0100.0
Week 20100.0100.0
Week 24100.0100.0
Week 2892.0100.0
SecondaryPercentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1) Through Week 28

OLTP; Normalization of LDH was defined as LDH ≤1.0 × ULN at each visit

Time frame:
Baseline (Day 1) through Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1) Through Week 28
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Baseline (Day 1)92.075.0
Pre-treatment92.083.0
Week 1100.092.0
Week 292.083.0
Week 483.083.0
Week 683.075.0
Week 8100.082.0
Week 10100.083.0
Week 1292.083.0
Week 1692.075.0
Week 20100.092.0
Week 24100.092.0
Week 2883.083.0
SecondaryAverage LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Baseline (Day 1) Through Week 28

OLTP

Time frame:
Baseline (Day 1) through Week 28
Reported as:
Mean · Units per Liter (U/L)
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Baseline (Day 1) Through Week 28
Units per Liter (U/L)Pozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Baseline (Day 1) Through Week 28238.18 ± 44.006244.42 ± 39.085
SecondaryAverage LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Week 4 Through Week 28

OLTP

Time frame:
Week 4 through Week 28
Reported as:
Mean · U/L
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Week 4 Through Week 28
U/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLTP Week 4 Through Week 28202.49 ± 38.272211.28 ± 34.280
SecondaryPercentage of Participants With Breakthrough Hemolysis From Baseline (Day 1) Through Week 28

OLTP Breakthrough hemolysis is defined as an increase in LDH with concomitant signs or symptoms associated with hemolysis: • An increase in LDH occurs when: * LDH ≥2 × ULN if pre-treatment LDH is ≤1.5 × ULN or * LDH ≥2 × ULN after initial achievement of LDH ≤1.5 × ULN if pre-treatment LDH is \>1.5 × ULN Signs or symptoms should correspond to those known to be associated with intravascular hemolysis due to Paroxysmal nocturnal hemoglobinuria (PNH) limited to the following: new onset or worsening fatigue, headache, dyspnea, hemoglobinuria, abdominal pain, scleral icterus, erectile dysfunction, chest pain, confusion, dysphagia, anemia including hemoglobin value significantly lower (ie, ≥2g/dL decrease) compared to patient's known baseline hemoglobin values, and thrombotic event.

Time frame:
Baseline (Day 1) through Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1) Through Week 28
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1) Through Week 288.30.0
SecondaryPercentage of Participants With Hemoglobin Stabilization From Baseline (Day 1) Through Week 28

OLTP Hemoglobin stabilization was defined as participants who did not receive an RBC transfusion and had no decrease in hemoglobin level of ≥2 grams per deciLiter (g/dL).

Time frame:
Baseline (Day 1) through Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1) Through Week 28
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1) Through Week 2875.091.7
SecondaryChange in Hemoglobin Levels From Baseline (Day 1) Through Week 28

OLTP

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · grams per Liter (g/L)
Change in Hemoglobin Levels From Baseline (Day 1) Through Week 28
grams per Liter (g/L)Pozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Change in Hemoglobin Levels From Baseline (Day 1) Through Week 28-1.3 ± 13.7710.3 ± 7.41
SecondaryPercentage of Participants With Transfusion Avoidance From Baseline (Day 1) Through Week 28

OLTP Not requiring a red blood cell (RBC) transfusion as per protocol algorithm

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Transfusion Avoidance From Baseline (Day 1) Through Week 28
Percentage of participantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Percentage of Participants With Transfusion Avoidance From Baseline (Day 1) Through Week 2883.3100.0
SecondaryRate of Red Blood Cells (RBCs) Transfused From Baseline (Day 1) to Week 28

OLTP Rate of RBCs transfused is defined as number of events per person-years of treatment. For each participant, the participant-years are the time from first dose date to week 28 (or early terminations visit if subject discontinued the study early) in the OLTP.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Number · Events per person-years of treatment
Rate of Red Blood Cells (RBCs) Transfused From Baseline (Day 1) to Week 28
Events per person-years of treatmentPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Rate of Red Blood Cells (RBCs) Transfused From Baseline (Day 1) to Week 281.284 (0.169 to 9.760)NA (NA to NA)
SecondaryNumber of Per-Protocol RBC Units Transfused From Baseline (Day 1) Through Week 28

OLTP

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · Units
Number of Per-Protocol RBC Units Transfused From Baseline (Day 1) Through Week 28
UnitsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Number of Per-Protocol RBC Units Transfused From Baseline (Day 1) Through Week 281.5 ± 3.730.0 ± 0.00
SecondaryChange in Total Complement Hemolysis Activity Assay (CH50) From Baseline (Day 1) Through Week 28

OLTP

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · Units per milliliter (U/mL)
Change in Total Complement Hemolysis Activity Assay (CH50) From Baseline (Day 1) Through Week 28
Units per milliliter (U/mL)Pozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Change in Total Complement Hemolysis Activity Assay (CH50) From Baseline (Day 1) Through Week 280.0 ± 0.0-0.1 ± 0.29
SecondaryChange in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1) Through Week 28

OLTP FACIT fatigue is a 13-item scale and for each item 4 is not at all fatigued to 0 very much fatigued. Higher FACIT-Fatigue scores indicate less fatigue (scores range from 0-52). A 5-point change is considered clinically meaningful.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · Score on a scale
Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1) Through Week 28
Score on a scalePozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1) Through Week 28-6.0 ± 10.09-2.0 ± 4.36
SecondaryChange in Global Health Status/Quality of Life Scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire Core 30 Items (EORTC QLQ-C30) From Baseline (Day 1) Through Week 28

OLTP EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · Score on a scale
Change in Global Health Status/Quality of Life Scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire Core 30 Items (EORTC QLQ-C30) From Baseline (Day 1) Through Week 28
Score on a scalePozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Change in Global Health Status/Quality of Life Scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire Core 30 Items (EORTC QLQ-C30) From Baseline (Day 1) Through Week 28-9.4 ± 23.33-1.9 ± 13.03
SecondaryChange in Physical Function (PF) Scores on the EORTC QLQ-C30 From Baseline (Day 1) Through Week 28

OLTP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

Time frame:
Baseline (Day 1) to Week 28
Reported as:
Mean · Score on a scale
Change in Physical Function (PF) Scores on the EORTC QLQ-C30 From Baseline (Day 1) Through Week 28
Score on a scalePozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Change in Physical Function (PF) Scores on the EORTC QLQ-C30 From Baseline (Day 1) Through Week 28-6.7 ± 19.190.7 ± 9.09
SecondaryConcentrations of Total Pozelimab in Serum on Week 28

OLTP

Time frame:
On Week 28
Reported as:
Mean · mg/L
Concentrations of Total Pozelimab in Serum on Week 28
mg/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Concentrations of Total Pozelimab in Serum on Week 28131 ± 74.858.2 ± 31.5
SecondaryConcentrations of Cemdisiran in Plasma on Week 28

OLTP

Time frame:
On Week 28
Reported as:
Mean · mg/L
Concentrations of Cemdisiran in Plasma on Week 28
mg/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Concentrations of Cemdisiran in Plasma on Week 28NA ± NANA ± NA
SecondaryConcentrations of Total C5 on Week 28

OLTP

Time frame:
On Week 28
Reported as:
Median · mg/L
Concentrations of Total C5 on Week 28
mg/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Concentrations of Total C5 on Week 280 (0 to 13.8)0 (0 to 0)
SecondaryNumber of Participants With Pozelimab Anti-Drug Antibody (ADA) Responses Over Time

OLTP and OLEP

Time frame:
Up to Week 52 (OLTP [ Week 0 - Week 28] + OLEP [Week 28 - Week 52])
Reported as:
Number · Participants
Number of Participants With Pozelimab Anti-Drug Antibody (ADA) Responses Over Time
ParticipantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Treatment-Boosted Response00
Treatment-Emergent Response00
SecondaryNumber of Participants With Cemdisiran Anti-Drug Antibody (ADA) Responses Over Time

OLTP and OLEP

Time frame:
Up to Week 52 (OLTP [ Week 0 - Week 28] + OLEP [Week 28 - Week 52])
Reported as:
Number · Participants
Number of Participants With Cemdisiran Anti-Drug Antibody (ADA) Responses Over Time
ParticipantsPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Treatment-Boosted Response00
Treatment-Emergent Response01
SecondaryPercentage of Participants With TEAEs for Participants Who Received Treatment Intensification

OLTP No participants received dose intensification during the study; Therefore, assessment of the safety of pozelimab + cemdisiran combination therapy in participants requiring dose intensification was not conducted.

Time frame:
Through Week 28

No measurements were reported for this outcome.

SecondaryChange of LDH From Baseline (Day 1e) to Week 24e

Optional Open-Label Extension Period (OLEP)

Time frame:
Baseline (Day 1e) to Week 24e
Reported as:
Mean · U/L
Change of LDH From Baseline (Day 1e) to Week 24e
U/LPozelimab Q4W + Cemdisiran
Change of LDH From Baseline (Day 1e) to Week 24e-18.2 ± 108.40
SecondaryPercent Change of LDH From OLEP Baseline (Day 1e) to Week 24e

OLEP; Percentage of change for units per liter (U/L)

Time frame:
Baseline (Day 1e) to Week 24e
Reported as:
Mean · Percentage of change
Percent Change of LDH From OLEP Baseline (Day 1e) to Week 24e
Percentage of changePozelimab Q4W + Cemdisiran
Percent Change of LDH From OLEP Baseline (Day 1e) to Week 24e-0.7 ± 20.60
SecondaryChange of LDH From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · U/L
Change of LDH From Baseline (Day 1e) to Week 52e
U/LPozelimab Q4W + Cemdisiran
Change of LDH From Baseline (Day 1e) to Week 52e-14.5 ± 105.90
SecondaryPercent Change of LDH From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · Percentage of change
Percent Change of LDH From Baseline (Day 1e) to Week 52e
Percentage of changePozelimab Q4W + Cemdisiran
Percent Change of LDH From Baseline (Day 1e) to Week 52e0.2 ± 19.49
SecondaryPercentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 24e

OLEP

Time frame:
Baseline (Day 1e) through Week 24e
Reported as:
Number · Percentage of Participants
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 24e
Percentage of ParticipantsPozelimab Q4W + Cemdisiran
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 24e95.7
SecondaryPercentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 52e

OLEP

Time frame:
Baseline (Day 1e) through Week 52e
Reported as:
Number · Percentage of Participants
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 52e
Percentage of ParticipantsPozelimab Q4W + Cemdisiran
Percentage of Participants Maintaining Adequate Control of Hemolysis From Baseline (Day 1e) Through Week 52e95.7
SecondaryPercentage of Participants With Adequate Control of Hemolysis at Each Visit From Baseline (Day 1e) Through Week 52e

OLEP Adequate control at a visit is defined as having LDH \<=1.5 x ULN at that visit

Time frame:
Baseline (Day 1e) through Week 52e
Reported as:
Number · Percentage of participants
Percentage of Participants With Adequate Control of Hemolysis at Each Visit From Baseline (Day 1e) Through Week 52e
Percentage of participantsPozelimab Q4W + Cemdisiran
OLEP Baseline (Day 1e)96.0
Week 8e100.0
Week 16e100.0
Week 24e100.0
Week 32e100.0
Week 40e100.0
Week 52e100.0
SecondaryPercentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1e) Through Week 52e

OLEP

Time frame:
Baseline (Day 1e) through week 52e
Reported as:
Number · Percentage of participants
Percentage of Participants With Normalization of LDH at Each Visit From Baseline (Day 1e) Through Week 52e
Percentage of participantsPozelimab Q4W + Cemdisiran
OLEP Baseline (Day 1e)87.0
Week 8e83.0
Week 16e82.0
Week 24e82.0
Week 32e86.0
Week 40e82.0
Week 52e82.0
SecondaryAverage LDH (U/L) Based on Area Under the Curve (AUC) From OLEP Baseline (Day 1e) Through Week 52e

OLEP

Time frame:
Baseline (Day 1e) through Week 52e
Reported as:
Mean · U/L
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLEP Baseline (Day 1e) Through Week 52e
U/LPozelimab Q4W + Cemdisiran
Average LDH (U/L) Based on Area Under the Curve (AUC) From OLEP Baseline (Day 1e) Through Week 52e154.63 ± 38.231
SecondaryPercentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 24e

OLEP

Time frame:
Baseline (Day 1e) through Week 24e
Reported as:
Number · Percentage of Participants
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 24e
Percentage of ParticipantsPozelimab Q4W + Cemdisiran
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 24e4.3
SecondaryPercentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 52e

OLEP

Time frame:
Baseline (Day 1e) through Week 52e
Reported as:
Number · Percentage of participants
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 52e
Percentage of participantsPozelimab Q4W + Cemdisiran
Percentage of Participants With Breakthrough Hemolysis From Baseline (Day 1e) Through Week 52e4.3
SecondaryPercentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 24e

OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels

Time frame:
Baseline (Day 1e) through Week 24e
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 24e
Percentage of participantsPozelimab Q4W + Cemdisiran
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 24e78.3
SecondaryPercentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 52e

OLEP Participants who did not receive RBC transfusion and had no decrease in hemoglobin levels

Time frame:
Baseline (Day 1e) through Week 52e
Reported as:
Number · Percentage of participants
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 52e
Percentage of participantsPozelimab Q4W + Cemdisiran
Percentage of Participants With Hemoglobin Stabilization From Baseline (Day 1e) Through Week 52e69.6
SecondaryChange in Hemoglobin Levels From Baseline (Day 1e) to Week 24e

OLEP

Time frame:
Baseline (Day 1e) to Week 24e
Reported as:
Mean · g/L
Change in Hemoglobin Levels From Baseline (Day 1e) to Week 24e
g/LPozelimab Q4W + Cemdisiran
Change in Hemoglobin Levels From Baseline (Day 1e) to Week 24e0.8 ± 15.63
SecondaryChange in Hemoglobin Levels From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · g/L
Change in Hemoglobin Levels From Baseline (Day 1e) to Week 52e
g/LPozelimab Q4W + Cemdisiran
Change in Hemoglobin Levels From Baseline (Day 1e) to Week 52e-0.6 ± 12.60
SecondaryPercentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 24e

OLEP Not requiring a RBC transfusion as per protocol algorithm

Time frame:
Baseline (Day 1e) through Week 24e
Reported as:
Number · Percentage of Participants
Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 24e
Percentage of ParticipantsPozelimab Q4W + Cemdisiran
Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 24e87.0
SecondaryPercentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 52e

OLEP Not requiring a RBC transfusion as per protocol algorithm

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Number · Percentage of Participants
Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 52e
Percentage of ParticipantsPozelimab Q4W + Cemdisiran
Percentage of Participants With Per-Protocol Transfusion Avoidance From Baseline (Day 1e) Through Week 52e87.0
SecondaryRate of RBCs Transfused From Baseline (Day 1e) to Week 24e

OLEP

Time frame:
Baseline (Day 1e) to Week 24e
Reported as:
Number · Events per person-years of treatment
Rate of RBCs Transfused From Baseline (Day 1e) to Week 24e
Events per person-years of treatmentPozelimab Q4W + Cemdisiran
Rate of RBCs Transfused From Baseline (Day 1e) to Week 24e0.591 (0.143 to 2.445)
SecondaryRate of RBCs Transfused From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Number · Events per person-years of treatment
Rate of RBCs Transfused From Baseline (Day 1e) to Week 52e
Events per person-years of treatmentPozelimab Q4W + Cemdisiran
Rate of RBCs Transfused From Baseline (Day 1e) to Week 52e0.506 (0.092 to 2.773)
SecondaryNumber of Units of RBCs Transfused From Baseline (Day 1e) to Week 24e

OLEP

Time frame:
Baseline (Day 1e) to Week 24e
Reported as:
Mean · Units
Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 24e
UnitsPozelimab Q4W + Cemdisiran
Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 24e0.4 ± 1.47
SecondaryNumber of Units of RBCs Transfused From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · Units
Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 52e
UnitsPozelimab Q4W + Cemdisiran
Number of Units of RBCs Transfused From Baseline (Day 1e) to Week 52e0.9 ± 3.95
SecondaryChange in CH50 From Baseline (Day 1e) to Week 16e

OLEP

Time frame:
Baseline (Day 1e) to Week 16e
Reported as:
Mean · U/mL
Change in CH50 From Baseline (Day 1e) to Week 16e
U/mLPozelimab Q4W + Cemdisiran
Change in CH50 From Baseline (Day 1e) to Week 16e0.0 ± 0.00
SecondaryChange in CH50 From Baseline (Day 1e) to Week 24e

OLEP

Time frame:
Baseline (Day 1e) to Week 24e

No measurements were reported for this outcome.

SecondaryChange in CH50 From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · U/mL
Change in CH50 From Baseline (Day 1e) to Week 52e
U/mLPozelimab Q4W + Cemdisiran
Change in CH50 From Baseline (Day 1e) to Week 52e0.0 ± 0.21
SecondaryPercent Change in CH50 From Baseline (Day 1e) to Week 16e

OLEP

Time frame:
Baseline (Day 1e) to Week 16e
Reported as:
Number · Percentage of change
Percent Change in CH50 From Baseline (Day 1e) to Week 16e
Percentage of changePozelimab Q4W + Cemdisiran
Percent Change in CH50 From Baseline (Day 1e) to Week 16eNA
SecondaryPercent Change in CH50 From Baseline (Day 1e) to Week 24e

OLEP

Time frame:
Baseline (Day 1e) to Week 24e
Reported as:
Number · Percentage of change
Percent Change in CH50 From Baseline (Day 1e) to Week 24e
Percentage of changePozelimab Q4W + Cemdisiran
Percent Change in CH50 From Baseline (Day 1e) to Week 24eNA
SecondaryPercent Change in CH50 From Baseline (Day 1e) to Week 52e

OLEP

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Number · Percentage of change
Percent Change in CH50 From Baseline (Day 1e) to Week 52e
Percentage of changePozelimab Q4W + Cemdisiran
Percent Change in CH50 From Baseline (Day 1e) to Week 52eNA
SecondaryChange in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1e) to Week 52e

OLEP; The FACIT-Fatigue is a 13-item, self-administered assessment of an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-Fatigue items are measured with a 5-point Likert scale ranging from 0 (not at all) to 4 (very much). Scores range from 0 to 52, with higher scores indicating less fatigue. A 5-point change is considered clinically meaningful.

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · Score on a scale
Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1e) to Week 52e
Score on a scalePozelimab Q4W + Cemdisiran
Change in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale From Baseline (Day 1e) to Week 52e-0.9 ± 5.95
SecondaryChange in GHS/QoL on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e

OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · Score on a scale
Change in GHS/QoL on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e
Score on a scalePozelimab Q4W + Cemdisiran
Change in GHS/QoL on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e6.0 ± 13.73
SecondaryChange in PF Scores on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e

OLEP; EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

Time frame:
Baseline (Day 1e) to Week 52e
Reported as:
Mean · Score on a scale
Change in PF Scores on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e
Score on a scalePozelimab Q4W + Cemdisiran
Change in PF Scores on the EORTC QLQ-C30 From Baseline (Day 1e) to Week 52e-0.3 ± 3.93
SecondaryPercentage of Participants With TEAEs Up to Week 52

OLEP

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With TEAEs Up to Week 52
Percentage of participantsPozelimab Q4W + Cemdisiran
Participants with any TEAE73.9
Participants with serious TEAE8.7
Participants with severe TEAE4.3
SecondaryConcentrations of Total Pozelimab in Serum on Week 52

OLEP

Time frame:
On Week 52
Reported as:
Mean · mg/L
Concentrations of Total Pozelimab in Serum on Week 52
mg/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Concentrations of Total Pozelimab in Serum on Week 5263.4 ± 35.658.6 ± 28.7
SecondaryConcentrations of Total C5 on Week 52

OLEP

Time frame:
On Week 52
Reported as:
Median · mg/L
Concentrations of Total C5 on Week 52
mg/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Concentrations of Total C5 on Week 520 (0 to 8.05)NA (NA to NA)
SecondaryConcentrations of Cemdisiran in Plasma on Week 52

OLEP

Time frame:
On Week 52
Reported as:
Mean · mg/L
Concentrations of Cemdisiran in Plasma on Week 52
mg/LPozelimab Q2W + CemdisiranPozelimab Q4W + Cemdisiran
Concentrations of Cemdisiran in Plasma on Week 52NA ± NANA ± NA

Adverse events

Collected over From first dose up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OLTP_Pozelimab Q2W + Cemdisiran0/12 (0%)3/12 (25%)8/12 (66.7%)
OLTP_Pozelimab Q4W + Cemdisiran0/12 (0%)0/12 (0%)5/12 (41.7%)
OLEP_Pozelimab Q4W + Cemdisiran0/23 (0%)2/23 (8.7%)10/23 (43.5%)
Most frequent serious events
Most frequent serious events
EventOLTP_Pozelimab Q2W + CemdisiranOLTP_Pozelimab Q4W + CemdisiranOLEP_Pozelimab Q4W + Cemdisiran
COVID-19Infections and infestations1/120/120/23
GastroenteritisInfections and infestations1/120/120/23
Upper respiratory tract infectionInfections and infestations1/120/120/23
HaemolysisBlood and lymphatic system disorders0/120/121/23
Anal fistulaGastrointestinal disorders0/120/121/23
Large intestine polypGastrointestinal disorders0/120/121/23
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOLTP_Pozelimab Q2W + CemdisiranOLTP_Pozelimab Q4W + CemdisiranOLEP_Pozelimab Q4W + Cemdisiran
COVID-19Infections and infestations2/121/124/23
Upper respiratory tract infectionInfections and infestations2/120/124/23
Injection site reactionGeneral disorders2/122/123/23
Chest painGeneral disorders0/121/120/23
ArthralgiaMusculoskeletal and connective tissue disorders0/121/120/23
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/121/120/23
MyalgiaMusculoskeletal and connective tissue disorders1/121/120/23
Muscle spasmsMusculoskeletal and connective tissue disorders1/120/120/23
Abdominal painGastrointestinal disorders0/121/120/23
Anal fistulaGastrointestinal disorders1/120/120/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pozelimab Q2W + CemdisiranPozelimab Q4W + CemdisiranTotal
Mean41.4 ± 16.8953.2 ± 16.3847.3 ± 17.34
Sex: Female, Male
Sex: Female, Male(Participants)Pozelimab Q2W + CemdisiranPozelimab Q4W + CemdisiranTotal
Female5611
Male7613
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pozelimab Q2W + CemdisiranPozelimab Q4W + CemdisiranTotal
Hispanic or Latino000
Not Hispanic or Latino121224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pozelimab Q2W + CemdisiranPozelimab Q4W + CemdisiranTotal
White112
Black or African American000
Asian101121
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Not Reported101
08

Study locations

13 sites
  • Prince of Wales Hospital
    Hong Kong, New Territories 550540, Hong Kong
  • D l Pesti Centrumk rh z Orsz gos Hematol giai s Infektol giai Int zet
    Budapest, Nagyvárad Tér 1 1907, Hungary
  • Samsung Medical Center
    Seoul, Seoul Teugbyeolsi 06351, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Yonsei University College of Medicine, Severance Hospital
    Seoul, 3722, Korea, Republic of
  • Ewha Womans University Medical Centre
    Seoul, 7985, Korea, Republic of
  • Hospital Miri
    Miri, Sarawak 98000, Malaysia
  • Hospital Sibu
    Sibu, Sarawak 96000, Malaysia
  • Hospital Sultanah Nur Zahirah
    Kuala Terengganu, Terengganu 20400, Malaysia
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
  • Chang Gung Memorial Hospital
    Taoyuan City, 333, Taiwan
  • St. James's University Hospital
    Leeds, West Yorkshire LS97TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Oct 2022, 14 months.

Results were first posted in Jan 2025, 2 years 2 months after primary completion. A results delay was requested in Oct 2023.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 14 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 23, 2021
StartActual
Jul 29, 2021
Primary completionActual
Oct 25, 2022
CompletionActual
Oct 18, 2023
Results delay requested
Oct 24, 2023
Results first posted
Jan 16, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04811716
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Jul 29, 2021
Primary completion
Oct 25, 2022
Completion
Oct 18, 2023
Results posted
Jan 16, 2025
Last update
Apr 8, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pozelimab · Cemdisiran

Start the discussion